Efficacy and safety of monotherapy with sirukumab, an anti-IL-6 cytokine monoclonal antibody, compared with adalimumab monotherapy in biologic-naive patients with active rheumatoid arthritis: results of a global, randomized, double-blind, parallel-group, phase 3 study

Efficacy and safety of monotherapy with sirukumab, an anti-IL-6 cytokine monoclonal antibody, compared with adalimumab monotherapy in biologic-naive patients with active rheumatoid arthritis: results of a global, randomized, double-blind, parallel-group, phase 3 study

Bibliographic Details
Main Authors: Taylor, P, Schiff, M, Wang, Q, Jiang, Y, Kurrasch, R, Daga, S, Rao, R, Hsu, B, Tak, P
Format: Conference item
Published: Wiley 2016

Similar Items